NFKB1 and chronic obstructive pulmonary disease: Therefore, the inhibition of p38 MAPK and NF-κB activation causes the suppression of inflammatory molecules, and, therefore, p38 MAPK and NF-κB signaling represent potential effective targets in COPD therapy.